paclitaxel has been researched along with rosiglitazone in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alemany, S; Caivano, M; Cohen, P; Rodriguez, C | 1 |
| Gaman, EA; Gleeson, JP; Obach, RS; Proctor, WR; Walsky, RL | 1 |
| Acampado, E; Cheng, Q; Davis, T; Eppihimer, M; Ezell, T; Finn, AV; Gold, HK; John, M; Karmali, V; Kolodgie, FD; Lajoie, S; Nakazawa, G; Polavarapu, R; Raghunathan, C; Virmani, R; Xu, X | 1 |
| Foti, RS; Rock, DA; VandenBrink, BM; Wahlstrom, JL; Wienkers, LC | 1 |
| Cho, HJ; Choi, YE; Kim, BK; Kim, HS; Kwon, YW; Lee, HC; Lee, SW; Muller, DN; Park, JB; Park, KW; Yang, HM; Youn, SW | 1 |
| Bridges, AS; Dees, EC; Herendeen, J; Hertz, DL; Hull, JH; Rollins, K; Walko, CM; Watkins, PB | 1 |
| Hu, J; Jing, X; Li, W; Su, P; Wang, X; Wu, X; Zhang, H; Zhang, X; Zhou, G | 1 |
| Apellániz-Ruiz, M; Bergmann, TK; Brøsen, K; Green, H; Ingelman-Sundberg, M; Johansson, I; Lee, MY; Rodríguez-Antona, C; Vikingsson, S | 1 |
| Badgeley, MA; Bagalkot, V; Deiuliis, JA; Kampfrath, T; Maiseyeu, A; Rajagopalan, S | 1 |
| Chen, N; Chen, SP; Li, DY; Liu, DQ; Sun, J; Tian, YK; Wang, XM; Ye, DW; Zhou, YQ | 1 |
1 review(s) available for paclitaxel and rosiglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
20 other study(ies) available for paclitaxel and rosiglitazone
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
15-Deoxy-Delta12,14-prostaglandin J2 regulates endogenous Cot MAPK kinase kinase 1 activity induced by lipopolysaccharide.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Carcinogens; Cell Division; Cell Line; Enzyme Activation; Enzyme Inhibitors; Fibrinolytic Agents; Gene Expression Regulation, Enzymologic; Indoles; Ligands; Lipopolysaccharides; Macrophages; Maleimides; MAP Kinase Kinase Kinases; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Precipitin Tests; Prostaglandin D2; Protein Isoforms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-raf; RNA, Messenger; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazolidinediones; Time Factors | 2003 |
Selective inhibition of human cytochrome P4502C8 by montelukast.
Topics: Acetates; Amodiaquine; Anti-Asthmatic Agents; Aryl Hydrocarbon Hydroxylases; Cyclopropanes; Cytochrome P-450 CYP2C8; Drug Interactions; Enzyme Inhibitors; Humans; In Vitro Techniques; Leukotriene Antagonists; Microsomes, Liver; Paclitaxel; Quinolines; Recombinant Proteins; Rosiglitazone; Sulfides; Thiazolidinediones | 2005 |
Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation.
Topics: Animals; Aorta; Cells, Cultured; Drug-Eluting Stents; Endothelial Cells; Graft Occlusion, Vascular; Heme Oxygenase-1; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Models, Biological; Paclitaxel; PPAR gamma; Protein Kinases; Proto-Oncogene Proteins c-akt; Rabbits; Rosiglitazone; Sirolimus; Thiazolidinediones; TOR Serine-Threonine Kinases; Tubulin Modulators | 2009 |
Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.
Topics: Acetates; Amodiaquine; Aryl Hydrocarbon Hydroxylases; Binding Sites; Carbamates; Cyclopropanes; Cytochrome P-450 CYP2C8; Drug Interactions; Humans; Microsomes, Liver; Paclitaxel; Piperidines; Quinolines; Rosiglitazone; Sensitivity and Specificity; Substrate Specificity; Sulfides; Thiazolidinediones | 2011 |
Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion.
Topics: Animals; Catheterization; Disease Models, Animal; Enzyme Activation; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Infusions, Intra-Arterial; Lipoproteins; Mitogen-Activated Protein Kinases; Models, Biological; Monocytes; Muscle, Smooth, Vascular; Paclitaxel; Phosphorylation; PPAR gamma; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rosiglitazone; Sirolimus; Thiazolidinediones; Thromboplastin; Umbilical Arteries | 2011 |
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cytochrome P-450 CYP2C8; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Hypoglycemic Agents; Male; Microsomes, Liver; Middle Aged; Models, Biological; Paclitaxel; Pilot Projects; Predictive Value of Tests; Rosiglitazone; Thiazolidinediones; Tubulin Modulators | 2012 |
Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes.
Topics: Active Transport, Cell Nucleus; Anilides; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; beta Catenin; Cell Line, Tumor; Cell Nucleus; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Frizzled Receptors; Humans; Ovarian Neoplasms; Paclitaxel; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription, Genetic; Wnt Proteins | 2015 |
Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.
Topics: Alleles; Amodiaquine; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Cytochrome P-450 CYP2C8; Dose-Response Relationship, Drug; Female; HEK293 Cells; Humans; Isoenzymes; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Risk Factors; Rosiglitazone; Substrate Specificity; Thiazolidinediones | 2015 |
Hybrid nanoparticles improve targeting to inflammatory macrophages through phagocytic signals.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Cell Line; Cholesterol; Cytokines; Fluorescein-5-isothiocyanate; Gadolinium; Macrophages; Mice, Inbred C57BL; Mice, Knockout; Nanoparticles; Obesity; Paclitaxel; Phagocytosis; Phosphatidylethanolamines; Phosphatidylserines; Phospholipases A2; Polyethylene Glycols; Polystyrenes; Rosiglitazone; Tamoxifen; Thiazolidinediones | 2015 |
PPARγ activation mitigates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of Nrf2/HO-1 signaling pathway.
Topics: Analgesics; Animals; Disease Models, Animal; Heme Oxygenase (Decyclizing); Hyperalgesia; Male; Neuralgia; NF-E2-Related Factor 2; Paclitaxel; Pain Perception; Pain Threshold; PPAR gamma; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Spinal Cord; Up-Regulation | 2020 |